🤔 EMPA KIDNEY analysis by CKD diagnosis

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)

🤔 EMPA Kidney sub-group analysis by DM and ACR status

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)

Freely Filtered does EMPA-Kidney

Freely Filtered 054: EMPA-Kidney. EMPA-Kidney is the last of the big three to report their Kidney Endpoints SGLT2i trial (CREDENCE for Cana, DAPA-CKD for Dapa, and now EMPA-Kidney for Empa) and it answers some questions that had previously been unanswered. Join the Filtrate as they tear it apart.

Another EMPA-Kidney Tweetorial

Friend of NephJC, Daniel Schwartz does a nice tweetorial on EMPA-Kidney

7 ways the EMPA-KIDNEY trial will impact clinical care in CKD

A Thread 🧵

Sources @NEJM @NephJC @DiabetesCanada @AmDiabetesAssn @goKDIGO @ESC_Journals @hswapnil @kidney_boy

— Daniel Schwartz (@drdschwartzmd) November 27, 2022

Flozins strike again!

If you missed the biggest NephJC of the year, at least read the highlights here.

If you only read one #TenTweetNephJC this year, make it this one.

EMPA-KIDNEY is one of those landmark trials it is worth knowing inside-out, but you can still rapidly catch up on the key findings & author tweetchat secrets in the thread below👇 pic.twitter.com/VL2u8BoCLw

— Nephrology Journal Club (@NephJC) November 22, 2022